PDCD1 and infection: Therefore, we herein compared infection outcomes and key immune parameters in pharmacologically immunosuppressed mice with invasive pulmonary mucormycosis (IPM) that were treated with PD-1 or PD-L1 inhibitors versus non-targeting isotype antibodies.